Published Date: 17 Feb 2023
Bhopal: Over 10,000...
Read Full NewsNew phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.
Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.
1.
Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.
2.
For treatment, the majority of cancer patients choose complementary therapies.
3.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
4.
CAR T Cells Produce 10-Year Remissions in Some With Lymphoma
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
2.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
3.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
4.
Exploring the Latest Treatments for Desmoid Tumors
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
2.
How Blood Tests Help Detect Hematological Disorders
3.
How Cancer Screening Supports Early Diagnosis
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation